Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
35+
Articles
18
Categories
Deep dives into peptide science — evidence-graded, honestly reported
We tested every peptide tracker app in 2026. Here's what we found, including where our competitors beat us.
The peptide tracker market went from empty to 15+ apps in 12 months. We tested them all and scored them on what matters: safety features, PK modelling, multi-compound support, and price. Pinned is ours. We're transparent about that.
Comprehensive outcome research with safety data and practical protocol references
Detailed compound profiles with mechanisms, safety data, and dosing protocols
Evidence-based supplement stacks designed to support your peptide protocols
Evidence-graded testosterone profiles by ester and formulation, with safety data and peptide alternatives
RFK said peptides are back. The FDA hasn't published the rule change yet. Here's what's actually happening.
The FDA's 2026 peptide reclassification is a regulatory process, not a completed rule change. Seven compounds face PCAC review in July 2026, legal access requires a prescription, and the grey market remains unchanged until the FDA publishes.
HPTA recovery after testosterone therapy takes far longer than forums claim. Established PCT has limits, and peptides offer a mechanistically compelling but clinically unproven layer on top.
Exogenous testosterone suppresses the hypothalamic-pituitary-testicular axis at every level. Recovery is measured in months to years, not weeks. This article maps the clinical timeline, examines where Kisspeptin-10, triptorelin, and GH secretagogues fit, and is honest about what the evidence does and does not support.
The same TRT protocol becomes a fundamentally different risk proposition at 30 than at 50. Here's where the calculus shifts, and where peptides start winning specific trades.
After 35, cardiovascular remodeling accelerates, prostate risk compounds, and HPTA recovery narrows. This article maps the age-stratified risk data for TRT and identifies where GH secretagogues, the Wolverine Stack, and Sermorelin offer lower-cost alternatives for specific outcomes.
You're spending $200–500/month on biological software and tracking it in a Notes app. The compounds aren't the problem. The total absence of protocol discipline is.
Peptide access exploded in 2026. Protocol discipline didn't follow. Most users are dosing from Reddit consensus, ignoring half-lives, missing timing windows, and running zero safety baselines. This article maps the specific failure modes, the insulin trap, the NO floor, the receptor ceiling, the sedentary trap, and what precision tracking actually looks like by comparison.
Two sister peptides from the same Cold War lab, one calms the emotional floor, the other raises the cognitive ceiling. The mechanistic case for stacking them is architecturally compelling. The clinical evidence for the combination doesn't exist yet.
Selank and Semax are sister heptapeptides engineered with the same glyproline stability tail but from opposite parent molecules, tuftsin (immune) and ACTH (stress). They converge on BDNF through completely different upstream pathways, covering complementary neurochemical territory. This article examines the mechanistic case for combining them, the cofactors that determine whether either signal lands, and where the evidence stops short.
For the high-performance community, the quest for longevity has evolved beyond the basic pillars of sleep and nutrition. We have moved into the era of precision signaling—using the body's own biochemical language to accelerate tissue repair and optimize metabolic flux.
For the high-performance community, the quest for longevity has evolved beyond the basic pillars of sleep and nutrition. We have moved into the era of precision signaling—using the body's own biochemi
For the sophisticated health optimizer, the narrative of the last few years has been dominated by the "incretin revolution." We have watched semaglutide and tirzepatide dismantle the traditional "willpower" myth of obesity. Yet, a frustrating biological reality has emerged: the "weight loss wall." Enter Retatrutide — the world's first triple agonist designed to re-engineer the metabolic equation entirely.
For the sophisticated health optimizer, the narrative of the last few years has been dominated by the "incretin revolution." We have watched semaglutide and tirzepatide dismantle the traditional "will
The biochemical cofactors your body needs to support FOXO4-DRI therapy.
Evidence-based supplement companion for FOXO4-DRI: a D-retro-inverso peptide that selectively kills senescent cells by disrupting the FOXO4-p53 survival interaction, triggering mitochondrial apoptosis in aged 'zombie' cells while sparing healthy tissue.
The biochemical cofactors your body needs to support Ipamorelin therapy.
Evidence-based supplement companion for Ipamorelin , a selective ghrelin mimetic that triggers your pituitary to release growth hormone without touching cortisol, prolactin, or appetite.
The biochemical cofactors your body needs to support CJC-1295 therapy.
Evidence-based supplement companion for CJC-1295 , a synthetic GHRH analog that tells your pituitary to release its own growth hormone, not inject someone else's.
The biochemical cofactors your body needs to support GHK-Cu therapy.
Evidence-based supplement companion for GHK-Cu : a naturally occurring tripeptide locked inside your collagen that modulates 4,192 human genes, acts as a safe copper chaperone, and signals systemic repair, with plasma levels dropping 60% between ages 20 and 60.
The biochemical cofactors your body needs to support Epitalon therapy.
Evidence-based supplement companion for Epitalon — a four-amino-acid peptide that activates telomerase, remodels chromatin, and restores melatonin synthesis from the pineal gland — addressing five hallmarks of aging simultaneously. The Russian clinical data spans 12–15 years. Independent Western replication barely exists.
The biochemical cofactors your body needs to support MOTS-c therapy.
Evidence-based supplement companion for MOTS-c — a 16-amino-acid mitochondrial messenger that mimics exercise at the cellular level — activating AMPK, reprogramming metabolism, and writing survival instructions directly into the nucleus. The science is striking. The stability problem is brutal.
The most prescribed testosterone ester outside the US, with a 4.5-7 day half-life that demands weekly dosing for stable levels. What the clinical data says about the hepcidin hijack, erythrocytosis, and why dosing frequency matters more than dose size.
Evidence-graded profile of testosterone enanthate: the hepcidin mechanism behind erythrocytosis, DHT and the scrotal paradox, dosing frequency pharmacokinetics, the TRAVERSE prostate saturation model, age-stratified risk, and peptide alternatives.